Help Us Protect Access to Sexual and Reproductive Health Care Today!
Jun 18
Written by Meghan Hynes Although health care professionals and institutions are evolving from treating addiction as a moral failing to treating it as a chronic disease in recent years, substance use during pregnancy remains misunderstood and heavily stigmatized. This stigmatization can negatively affect how health care professionals perceive patients with substance use disorders (SUDs) and…
May 28
Written by Kenya Lyons, MD The administration of mifepristone followed by misoprostol is a highly effective regimen for the management of first-trimester miscarriage and medication abortion.1 However, even prior to the onset of legal challenges to mifepristone, including FDA v. Alliance for Hippocratic Medicine, the search for alternative therapies existed. This has been driven by…
May 21
Written by Veronica Flake, MD Ulipristal Acetate (ella, UPA) is an effective emergency contraception (EC) method, given as a one-time, 30-mg dose, which can be used for up to 120 hours after unprotected sexual intercourse to prevent pregnancy. UPA is a selective progesterone receptor modulator with antagonistic and partial agonistic effects that prevents or delays…
May 10
Some people prefer to take hormonal birth control without estrogen. This fact sheet highlights the progestin-only options that are available. Spanish: Updated 2024 Reading Grade Level (Flesch-Kincaid Grade Level): 6.2 Sources: CDC – Injectables – US SPR – Reproductive Health. Centers for Disease Control and Prevention. https://www.cdc.gov/reproductivehealth/contraception/mmwr/spr/injectables.html. Published May 20, 2021. Accessed…
Apr 23
This resource from the University of California San Francisco compares tubal sterilization with long-acting reversible contraceptive (LARC) methods like the IUD and Implant.
Apr 23
Written by Brandy Bautista This article was published in April 2024, before the Supreme Court released its ruling in Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration on June 13th. In its ruling, the Supreme Court unanimously rejected the challenge to mifepristone access. While we celebrate this decision, we know this will not…
Apr 16
Since the Supreme Court overturned Roe v. Wade, medical providers in states where abortion is banned or severely restricted have struggled to understand how state laws apply to them and their patients. This resource from the Abortion Defense Network aims to provide clarification, where possible, of what conduct is permitted in the states where the…
Apr 16
By Joi C. Spaulding MD, MS Opill, a daily progestin-only birth control pill (POP), was first approved for over-the-counter (OTC) use by the United States Food and Drug Administration (FDA) on July 13, 2023. As of March 2024, the pill is now available to people of all ages to purchase at retailers online and in…
Apr 16
This poster compares birth control choices based on efficacy, cost, side effects, and other patient-focused factors.
Mar 26
Written by Rebecca Wang, JD, Senior Legal Support Counsel and Lauren Paulk, JD, Senior Research Counsel Mandatory reporting is not an evidence-based practice. Neither is punishing providers for a failure to report. Still, healthcare provider reports to Child Protective Services of infants have increased substantially over the last decade.¹ This is despite only two states…